Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 1.46
ITMN's Cash to Debt is ranked higher than
59% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. ITMN: 1.46 )
ITMN' s 10-Year Cash to Debt Range
Min: 0.65   Max: No Debt
Current: 1.46

Equity to Asset 0.29
ITMN's Equity to Asset is ranked higher than
52% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ITMN: 0.29 )
ITMN' s 10-Year Equity to Asset Range
Min: -0.92   Max: 0.97
Current: 0.29

-0.92
0.97
F-Score: 5
Z-Score: 0.46
M-Score: -0.97
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -282.38
ITMN's Operating margin (%) is ranked higher than
60% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. ITMN: -282.38 )
ITMN' s 10-Year Operating margin (%) Range
Min: -2967.17   Max: 48.26
Current: -282.38

-2967.17
48.26
Net-margin (%) -312.16
ITMN's Net-margin (%) is ranked higher than
59% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. ITMN: -312.16 )
ITMN' s 10-Year Net-margin (%) Range
Min: -2862.47   Max: 51.15
Current: -312.16

-2862.47
51.15
ROE (%) -163.51
ITMN's ROE (%) is ranked higher than
50% of the 808 Companies
in the Global Biotechnology industry.

( Industry Median: -21.52 vs. ITMN: -163.51 )
ITMN' s 10-Year ROE (%) Range
Min: -226.31   Max: 81.97
Current: -163.51

-226.31
81.97
ROA (%) -47.46
ITMN's ROA (%) is ranked higher than
60% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. ITMN: -47.46 )
ITMN' s 10-Year ROA (%) Range
Min: -106.78   Max: 40.1
Current: -47.46

-106.78
40.1
ROC (Joel Greenblatt) (%) -4220.65
ITMN's ROC (Joel Greenblatt) (%) is ranked higher than
54% of the 868 Companies
in the Global Biotechnology industry.

( Industry Median: -189.80 vs. ITMN: -4220.65 )
ITMN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -6853.27   Max: 9266.21
Current: -4220.65

-6853.27
9266.21
Revenue Growth (%) -39.60
ITMN's Revenue Growth (%) is ranked higher than
59% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -0.40 vs. ITMN: -39.60 )
ITMN' s 10-Year Revenue Growth (%) Range
Min: -58.3   Max: 91.6
Current: -39.6

-58.3
91.6
» ITMN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

ITMN Guru Trades in Q1 2013

Louis Moore Bacon 200,000 sh (+300%)
Steven Cohen 3,078,962 sh (+206.67%)
PRIMECAP Management 5,643,289 sh (+77.69%)
Jim Simons Sold Out
Columbia Wanger 2,692,000 sh (-1.32%)
» More
Q2 2013

ITMN Guru Trades in Q2 2013

PRIMECAP Management 6,122,100 sh (+8.48%)
Columbia Wanger 2,692,000 sh (unchged)
Louis Moore Bacon Sold Out
Stanley Druckenmiller Sold Out
Steven Cohen 1,979,500 sh (-35.71%)
» More
Q3 2013

ITMN Guru Trades in Q3 2013

PRIMECAP Management 6,452,100 sh (+5.39%)
Columbia Wanger 2,770,000 sh (+2.9%)
Steven Cohen 447,700 sh (-77.38%)
» More
Q4 2013

ITMN Guru Trades in Q4 2013

PRIMECAP Management 6,472,100 sh (+0.31%)
Steven Cohen Sold Out
Columbia Wanger 2,612,000 sh (-5.7%)
» More
» Details

Insider Trades

Latest Guru Trades with ITMN

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
PRIMECAP Management 2013-03-31 Add 77.69%0.03%$8.39 - $10.74 $ 30.83223%5643289
PRIMECAP Management 2012-03-31 Add 177.48%0.04%$12.35 - $16.64 $ 30.83124%2907700
PRIMECAP Management 2011-09-30 Add 31.54%0.01%$20.78 - $37.15 $ 30.839%983900
PRIMECAP Management 2011-06-30 Add 53.28%0.01%$32.71 - $51.08 $ 30.83-23%748000
George Soros 2011-06-30 Sold Out $32.71 - $51.08 $ 30.83-23%0
George Soros 2011-03-31 New Buy0.07%$35.09 - $47.13 $ 30.83-22%125000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 20.50
ITMN's P/B is ranked lower than
72% of the 787 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. ITMN: 20.50 )
ITMN' s 10-Year P/B Range
Min: 2.98   Max: 27.19
Current: 20.5

2.98
27.19
P/S 35.71
ITMN's P/S is ranked lower than
70% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: 10.38 vs. ITMN: 35.71 )
ITMN' s 10-Year P/S Range
Min: 2.19   Max: 110.21
Current: 35.71

2.19
110.21
EV-to-EBIT 43.50
ITMN's EV-to-EBIT is ranked lower than
69% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. ITMN: 43.50 )
ITMN' s 10-Year EV-to-EBIT Range
Min: 7.4   Max: 26.3
Current: 43.5

7.4
26.3

Valuation & Return

vs
industry
vs
history
Price/Net Cash 47.40
ITMN's Price/Net Cash is ranked lower than
84% of the 476 Companies
in the Global Biotechnology industry.

( Industry Median: 9.10 vs. ITMN: 47.40 )
ITMN' s 10-Year Price/Net Cash Range
Min: 5.45   Max: 60.56
Current: 47.4

5.45
60.56
Price/Net Current Asset Value 34.30
ITMN's Price/Net Current Asset Value is ranked lower than
78% of the 520 Companies
in the Global Biotechnology industry.

( Industry Median: 9.30 vs. ITMN: 34.30 )
ITMN' s 10-Year Price/Net Current Asset Value Range
Min: 5.25   Max: 30.28
Current: 34.3

5.25
30.28
Price/Tangible Book 23.50
ITMN's Price/Tangible Book is ranked lower than
84% of the 727 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. ITMN: 23.50 )
ITMN' s 10-Year Price/Tangible Book Range
Min: 4.6   Max: 18.26
Current: 23.5

4.6
18.26
Price/Median PS Value 3.60
ITMN's Price/Median PS Value is ranked lower than
69% of the 717 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. ITMN: 3.60 )
ITMN' s 10-Year Price/Median PS Value Range
Min: 0.32   Max: 8.39
Current: 3.6

0.32
8.39
Earnings Yield (Greenblatt) 2.30
ITMN's Earnings Yield (Greenblatt) is ranked lower than
56% of the 379 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. ITMN: 2.30 )
ITMN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.3   Max: 13.5
Current: 2.3

2.3
13.5
Forward Rate of Return (Yacktman) -5.86
ITMN's Forward Rate of Return (Yacktman) is ranked higher than
78% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. ITMN: -5.86 )
ITMN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -15.4   Max: -3.7
Current: -5.86

-15.4
-3.7

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:IUX.Germany
InterMune, Inc was incorporated in California in 1998 and reincorporated in Delaware in 2000 in connection with its initial public offering. InterMune is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases. The Company's business is mainly focused on the development and commercialization of therapies within the specialized areas of pulmonology and orphan fibrotic diseases. It has an advanced-stage product candidate in pulmonology, pirfenidone that was granted marketing authorization effective February 2011 in all 27 member countries of the European Union for the treatment of adults with mild to moderate idiopathic pulmonary fibrosis. Pirfenidone is an orally active, small molecule compound under development for the treatment of idiopathic pulmonary fibrosis. Pirfenidone, a treatment for IPF, a progressive and fatal lung disease, has completed the global Phase 3 CAPACITY clinical development program. Actimmune is currently approved in the United States for the treatment of chronic granulomatous disease and severe, malignant osteopetrosis. Actimmune is also approved for commercial use in both indications in numerous other countries. CGD is a life-threatening congenital disorder that causes patients, mainly children, to be vulnerable to severe, recurrent bacterial and fungal infections. This results in frequent and prolonged hospitalizations and commonly results in death. Severe, malignant osteopetrosis is a life-threatening, congenital disorder that mainly affects children. This disease results in increased susceptibility to infection and an overgrowth of bony structures that might lead to blindness and/or deafness. The FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries impose substantial requirements upon the clinical development, manufacture and marketing of pharmaceutical products.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide